Literature DB >> 9755251

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.

K Ishii1, D Rosa, Y Watanabe, T Katayama, H Harada, C Wyatt, K Kiyosawa, H Aizaki, Y Matsuura, M Houghton, S Abrignani, T Miyamura.   

Abstract

Most cases of hepatitis C virus (HCV) infection result in chronic disease; however, a very small fraction of patients naturally clear the virus and resolve chronic hepatitis. In an attempt to correlate immune response with chronic disease resolution, we compared the antibody response in patients with different outcomes of the infection. Antibody responses to HCV structural proteins were assessed in 34 patients originally diagnosed with acute hepatitis. Five cases resolved acute infection, 22 developed chronic hepatitis, and 7 naturally resolved chronic hepatitis C. To estimate HCV neutralizing antibodies we used the neutralization of binding (NOB) assay, which evaluates inhibition of the envelope-2 protein binding to human cells. Enzyme-linked immunosorbent assay was used for the quantitative assessment of serum antibodies. The presence of HCV RNA was ascertained by reverse transcription-polymerase chain reaction. In 6 of 7 patients naturally recovered from chronic hepatitis C, the emergence and the persistence (for more than 3 months) of high serum titers (>1/600) of NOB antibodies coincided with virus clearance and clinical resolution of hepatitis. NOB antibody activity was observed in only 2 of 5 patients recovered from acute hepatitis C. Chronic patients who did not show any resolution during the course of the study developed low or no NOB antibodies. Because of the correlation between prolonged high NOB titers and natural resolution of chronic hepatitis C, vaccination or passive immunization aimed at high titers of NOB antibodies may be valuable new therapeutic approaches for chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755251     DOI: 10.1002/hep.510280429

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  32 in total

1.  Receptors for hepatitis C virus.

Authors:  I M Jones; C Chan-Fook; W R Jiang; B E Clarke
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Authors:  Mario Perotti; Nicasio Mancini; Roberta A Diotti; Alexander W Tarr; Jonathan K Ball; Ania Owsianka; R Adair; Arvind H Patel; Massimo Clementi; Roberto Burioni
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

3.  Structure-function analysis of hepatitis C virus envelope-CD81 binding.

Authors:  R Petracca; F Falugi; G Galli; N Norais; D Rosa; S Campagnoli; V Burgio; E Di Stasio; B Giardina; M Houghton; S Abrignani; G Grandi
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease.

Authors:  H L Tillmann; D F Chen; C Trautwein; V Kliem; A Grundey; A Berning-Haag; K Böker; S Kubicka; L Pastucha; W Stangel; M P Manns
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

5.  Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes.

Authors:  Bertrand Saunier; Miriam Triyatni; Luca Ulianich; Padma Maruvada; Paul Yen; Leonard D Kohn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 7.  The hepatitis C virus persistence: how to evade the immune system?

Authors:  Nicole Pavio; Michael M C Lai
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

8.  Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Authors:  Nicasio Mancini; Roberta A Diotti; Mario Perotti; Giuseppe Sautto; Nicola Clementi; Giovanni Nitti; Arvind H Patel; Jonathan K Ball; Massimo Clementi; Roberto Burioni
Journal:  PLoS One       Date:  2009-12-11       Impact factor: 3.240

9.  In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.

Authors:  Meital Gal-Tanamy; Zhen-Yong Keck; MinKyung Yi; Jane A McKeating; Arvind H Patel; Steven K H Foung; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-03       Impact factor: 11.205

10.  HCV antibody response and genotype distribution in different areas and races of China.

Authors:  Leili Jia; Jiyun Yu; Jinliang Yang; Hongbin Song; Xuelin Liu; Yong Wang; Yuanyong Xu; Chuanfu Zhang; Yanwei Zhong; Qiao Li
Journal:  Int J Biol Sci       Date:  2009-06-13       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.